Citadel Advisors
SMMT icon

Citadel Advisors’s Summit Therapeutics SMMT Stock Holding History

Citadel Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Sell
113,600
-303,900
-73% -$4.91M ﹤0.01% 5926
2025
Q4 		$7.3M Sell
417,500
-308,900
-43% -$5.81M ﹤0.01% 3700
2025
Q3 		$15M Buy
726,400
+332,700
+85% +$8.07M ﹤0.01% 2684
2025
Q2 		$8.38M Sell
393,700
-900
-0.2% -$20.5K ﹤0.01% 3284
2025
Q1 		$7.61M Buy
394,600
+79,300
+25% +$1.59M ﹤0.01% 3238
2024
Q4 		$5.63M Sell
315,300
-142,500
-31% -$2.76M ﹤0.01% 3768
2024
Q3 		$10M Buy
457,800
+392,300
+599% +$5.49M ﹤0.01% 2888
2024
Q2 		$511K Buy
65,500
+61,800
+1,670% +$334K ﹤0.01% 7995
2024
Q1 		$15.3K Buy
3,700
+3,600
+3,600% +$14.3K ﹤0.01% 13196
2023
Q4 		$261 Buy
+100
New +$206 ﹤0.01% 14070
2023
Q2 		– Sell
-8,500
Closed -$14.9K – 15150
2023
Q1 		$14.9K Sell
8,500
-118,500
-93% -$323K ﹤0.01% 13276
2022
Q4 		$540K Buy
+127,000
New +$231K ﹤0.01% 8078
2022
Q1 		– Sell
-15,700
Closed -$42K – 14498
2021
Q4 		$42K Sell
15,700
-8,300
-35% -$39.9K ﹤0.01% 13343
2021
Q3 		$120K Sell
24,000
-6,700
-22% -$48.1K ﹤0.01% 12647
2021
Q2 		$229K Buy
+30,700
New +$201K ﹤0.01% 11870

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's SMMT Position: Q1 2026 in Review

Citadel Advisors reduced its Summit Therapeutics (SMMT) stake by 82% in Q1 2026, selling an estimated $32.9M and leaving 441,743 shares worth $8.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Citadel Advisors first reported a position in SMMT in Q4 2018 and has held it in 17 quarters since. The position peaked at $43.3M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Citadel Advisors held 441,743 shares of Summit Therapeutics worth $8.38M as of Q1 2026.
  • Citadel Advisors sold 2,033,965 Summit Therapeutics shares in Q1 2026, an estimated $32.9M.
  • Summit Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3504 holding.
  • Citadel Advisors first reported a position in Summit Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Citadel Advisors's Summit Therapeutics position peaked at $43.3M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.